Common genetic differences affect vulnerability to childhood leukemia, new study shows

By focusing on molecular differences that define distinct types of childhood leukemia, scientists have discovered that vulnerability to one type of the cancer or another depends on something as simple as which form of a single enzyme a child inherits.

The discovery, led by a molecular epidemiologist at the University of California, San Francisco, highlights the impact even minor genetic variation can have on disease, and also shows how distinguishing subtle disease differences can help reveal causes that would otherwise be masked, the scientists say.

The research indicates that children are protected against different types of leukemia depending on which form of an enzyme they have for metabolizing folic acid.

The research is being presented March 26 at the annual meeting of the American Association for Cancer Research, and is being published March 27 in the Proceedings of the National Academy of Sciences.

"Currently we understand almost nothing about the causes of childhood leukemia, but such an understanding is essential if we hope to prevent this tragic disease," said Joseph Wiemels, PhD, lead author on the paper and assistant professor of epidemiology and biostatistics at UCSF."Our research suggests that scrutiny of genetic changes in leukemia cells -- at the DNA level -- can reveal potential causes specific to each type of leukemia."

Wiemels collaborated on the research with colleagues in England and Scotland.

The United States is among the countries with the highest rates of childhood leukemia in the world, Wiemels said, with about 3,500 children in the U.S. developing the cancer each year. Cancer biologists now recognize at least three subtypes of childhood leukemia, based on different abnormalities in the chromosomes. Each subtype has a different prognosis and treatment protocol, but causes remain unknown and treatments often create other serious medical problems.

Until now, there has been no indication that these three leu

Contact: Wallace Ravven

Page: 1 2 3

Related biology news :

1. Common cold virus can cause polio in mice when injected into muscles
2. Common call for action on European Research Council (ERC)
3. Common therapy for HIV associated with cervical abnormality regression
4. Common chemicals morphing into potential toxins in Arctic
5. Common worm provides insights into salmonella virulence
6. Common virus may contribute to uncommon bone disease in children
7. Common airborne substance makes asthmatics more sensitive to house dust mites: study
8. Common genetic damages in non-dividing cells lead to the creation of mutant proteins
9. Common nutrients fed to pregnant mice altered their offsprings coat color
10. Common treatment for depression is safe and effective for Alzheimers patients
11. Common gene variant increases risk of atherosclerosis

Post Your Comments:

(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: